145 related articles for article (PubMed ID: 19091899)
1. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Morrison MS; Ricketts SA; Barnett J; Cuthbertson A; Tessier J; Wedge SR
J Nucl Med; 2009 Jan; 50(1):116-22. PubMed ID: 19091899
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
Kenny LM; Coombes RC; Oulie I; Contractor KB; Miller M; Spinks TJ; McParland B; Cohen PS; Hui AM; Palmieri C; Osman S; Glaser M; Turton D; Al-Nahhas A; Aboagye EO
J Nucl Med; 2008 Jun; 49(6):879-86. PubMed ID: 18483090
[TBL] [Abstract][Full Text] [Related]
4. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
5. MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice.
Yang G; Nie P; Kong Y; Sun H; Hou G; Han J
Tumour Biol; 2015 May; 36(5):3285-91. PubMed ID: 25501513
[TBL] [Abstract][Full Text] [Related]
6. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
7. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice.
Lee KH; Ko BH; Paik JY; Jung KH; Choe YS; Choi Y; Kim BT
J Nucl Med; 2005 Sep; 46(9):1531-6. PubMed ID: 16157537
[TBL] [Abstract][Full Text] [Related]
8. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS
J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268
[TBL] [Abstract][Full Text] [Related]
9. (18) F labeled RGD-A7R peptide for dual integrin and VEGF-targeted tumor imaging in mice bearing U87MG tumors.
Ma Y; Liang S; Guo J; Guo R; Wang H
J Labelled Comp Radiopharm; 2014 Sep; 57(11):627-31. PubMed ID: 25294311
[TBL] [Abstract][Full Text] [Related]
10. PET imaging of early response to the tyrosine kinase inhibitor ZD4190.
Yang M; Gao H; Yan Y; Sun X; Chen K; Quan Q; Lang L; Kiesewetter D; Niu G; Chen X
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1237-47. PubMed ID: 21360246
[TBL] [Abstract][Full Text] [Related]
11. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X
J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494
[TBL] [Abstract][Full Text] [Related]
12. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
13. Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of
Warnders FJ; Terwisscha van Scheltinga AGT; Knuehl C; van Roy M; de Vries EFJ; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
J Nucl Med; 2017 Aug; 58(8):1210-1215. PubMed ID: 28360206
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
15. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice.
Jeong JM; Hong MK; Chang YS; Lee YS; Kim YJ; Cheon GJ; Lee DS; Chung JK; Lee MC
J Nucl Med; 2008 May; 49(5):830-6. PubMed ID: 18413379
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.
Sugiyama M; Sakahara H; Sato K; Harada N; Fukumoto D; Kakiuchi T; Hirano T; Kohno E; Tsukada H
J Nucl Med; 2004 Oct; 45(10):1754-8. PubMed ID: 15471845
[TBL] [Abstract][Full Text] [Related]
17. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
Li F; Jiang S; Zu Y; Lee DY; Li Z
J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
[TBL] [Abstract][Full Text] [Related]
18. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
19. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
20. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.
Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS
J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
